We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+10.81%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$7.37B
AUM Growth
+$626M
Cap. Flow
+$276M
Cap. Flow %
3.75%
Top 10 Hldgs %
69.13%
Holding
47
New
6
Increased
11
Reduced
7
Closed
4

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$126M
2
KRYS icon
Krystal Biotech
KRYS
+$82.8M
3
ROIV icon
Roivant Sciences
ROIV
+$51.9M
4
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$46.4M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$44.1M

Top Sells

Rank Stock Value
1
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$60.5M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$41M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$13.9M
4
NUVL
Nuvalent
NUVL
+$10.9M
5
ARGX icon
argenx
ARGX
+$9.44M

Sector Composition

Rank Sector Weight
1 Healthcare 99.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
$1.01B 13.73%
11,111,111
– –
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$720M 9.77%
7,000,000
– –
UTHR icon
3
United Therapeutics
UTHR
$25.9B
$642M 8.71%
2,909,999
+39,999
+1% +$8.86M
SRPT icon
4
Sarepta Therapeutics
SRPT
$1.64B
$530M 7.19%
4,627,888
+977,888
+27% +$126M
ARGX icon
5
argenx
ARGX
$54.9B
$492M 6.68%
1,263,500
-24,000
-2% -$9.44M
MDGL icon
6
Madrigal Pharmaceuticals
MDGL
$12.4B
$350M 4.75%
1,515,151
-151,515
-9% -$41M
BMRN icon
7
BioMarin Pharmaceuticals
BMRN
$11.9B
$347M 4.7%
4,000,000
+55,000
+1% +$5.18M
FOLD
8
DELISTED
Amicus Therapeutics
FOLD
$344M 4.67%
27,400,000
+100,000
+0.4% +$1.19M
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
$339M 4.59%
1,759,606
-42,300
-2% -$8.4M
ASND icon
10
Ascendis Pharma A/S
ASND
$16.6B
$320M 4.34%
3,580,555
+255,555
+8% +$22.2M
ISEE
11
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$317M 4.3%
8,050,000
+1,250,000
+18% +$44.1M
KRYS icon
12
Krystal Biotech
KRYS
$10.6B
$301M 4.08%
2,560,811
+810,811
+46% +$82.8M
ALNY icon
13
Alnylam Pharmaceuticals
ALNY
$38.1B
$210M 2.85%
1,105,000
– –
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$201M 2.72%
5,555,555
– –
XENE icon
15
Xenon Pharmaceuticals
XENE
$6.16B
$189M 2.56%
4,900,000
– –
CBAY
16
DELISTED
Cymabay Therapeutics
CBAY
$113M 1.53%
10,300,000
– –
DICE
17
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$102M 1.39%
2,199,342
-1,750,658
-44% -$60.5M
KYMR icon
18
Kymera Therapeutics
KYMR
$8.6B
$88.6M 1.2%
3,855,000
– –
MLTX icon
19
MoonLake Immunotherapeutics
MLTX
$1.58B
$88M 1.19%
+1,725,000
New +$46.4M
BCRX icon
20
BioCryst Pharmaceuticals
BCRX
$2.43B
$84.9M 1.15%
12,055,000
+1,635,000
+16% +$13.1M
NUVL
21
DELISTED
Nuvalent
NUVL
$67.5M 0.92%
1,600,000
-288,888
-15% -$10.9M
ROIV icon
22
Roivant Sciences
ROIV
$23.7B
$58.5M 0.79%
+5,806,162
New +$51.9M
SNDX icon
23
Syndax Pharmaceuticals
SNDX
$1.67B
$55.5M 0.75%
2,650,000
– –
IOVA icon
24
Iovance Biotherapeutics
IOVA
$2.03B
$47.2M 0.64%
6,700,000
-320,000
-5% -$2.29M
MNKD icon
25
MannKind Corp
MNKD
$1.2B
$37M 0.5%
9,100,000
– –
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q2 2023 Portfolio in Review

As of Q2 2023, Avoro Capital Advisors held 47 positions worth $7.37B, up 9.3% from $6.75B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Avoro Capital Advisors deployed $276M of net new capital in Q2 2023, opening 6 new positions and adding to 11 existing holdings. Its largest new stake was Roivant Sciences: 5,806,162 shares worth $58.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was DICE Therapeutics, Inc. Common Stock, an estimated $60.5M trimmed.

  • Avoro Capital Advisors's largest Q2 2023 buy was Roivant Sciences: 5,806,162 shares worth $58.5M.
  • Avoro Capital Advisors added most to Sarepta Therapeutics in Q2 2023, an estimated $126M increase.
  • Avoro Capital Advisors's biggest Q2 2023 reduction was DICE Therapeutics, Inc. Common Stock, cutting an estimated $60.5M.
  • Avoro Capital Advisors fully exited Amylyx Pharmaceuticals in Q2 2023, selling an estimated $13.9M.
  • Avoro Capital Advisors's ten largest holdings make up 69% of its $7.37B portfolio in Q2 2023.
  • Avoro Capital Advisors opened 6 new positions and closed 4 in Q2 2023.
  • Avoro Capital Advisors's portfolio value rose 9.3% quarter-over-quarter to $7.37B.

Based on Avoro Capital Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.